CD5: A New Partner for IL-6

Kazuya Masuda; Tadamitsu Kishimoto

doi:10.1016/j.immuni.2016.03.011

CD5: A New Partner for IL-6

Immunity. 2016 Apr 19;44(4):720-2. doi: 10.1016/j.immuni.2016.03.011.

Authors

Kazuya Masuda¹, Tadamitsu Kishimoto²

Affiliations

¹ Laboratory of Immune Regulation, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan.
² Laboratory of Immune Regulation, World Premier International (WPI) Immunology Frontier Research Center (IFReC), Osaka University, Osaka 565-0871, Japan. Electronic address: kishimoto@ifrec.osaka-u.ac.jp.

PMID: 27096313
DOI: 10.1016/j.immuni.2016.03.011

Abstract

IL-6-STAT3 axis is known as a key factor of tumor progression. In this issue of Immunity, Yu and colleagues (2016) show that IL-6-binding CD5, rather than IL-6 receptor-α in B cells, amplifies STAT3 activation via JAK-STAT signaling to promote cancer.

Publication types

Comment

MeSH terms

B-Lymphocytes / immunology
Humans
Interleukin-6*
Phosphorylation
Receptors, Interleukin-6
STAT3 Transcription Factor / metabolism*
Signal Transduction / immunology

Substances

Interleukin-6
Receptors, Interleukin-6
STAT3 Transcription Factor